Anti-CD19 Antibody-T-cell Receptor-expressing T-cells ET019003

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of T-lymphocytes that have been engineered by incorporating an as of yet undisclosed co-stimulatory molecule into T-cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) structure (ET190L1), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 AbTCR-expressing T-cells ET019003 targets and binds to CD19-expressing tumor cells. This results in cytotoxic T-lymphocyte (CTL)-mediated elimination of CD19-positive tumor cells. The binding to CD19-expressing tumor cells may also activate the undisclosed costimulatory domain, leading to further T-cell proliferation. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies. ET019003 is able to match the anticancer activity of chimeric antigen receptor (CAR) T-cells, while they are less likely to stimulate cytokine release syndrome (CRS) and less likely to cause cytokine-related toxicities.

**Synonyms:** - Anti-CD19 AbTCR-expressing T-cells ET019003 - Anti-CD19 T-cells ET019003 - Anti-CD19-TCR T-cells ET019003 - CD19-targeted T-cells ET019003 - ET 019003 - ET-019003 - ET019003 - ET019003-T Cells